关注
Jennifer Litton
Jennifer Litton
其他姓名Jennifer K Litton
The University of Texas MD Anderson Cancer Center
在 mdanderson.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
JK Litton, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, ...
New England Journal of Medicine 379 (8), 753-763, 2018
18452018
PD-L1 expression in triple-negative breast cancer
EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ...
Cancer immunology research 2 (4), 361-370, 2014
13302014
Breast cancer before age 40 years
CK Anders, R Johnson, J Litton, M Phillips, A Bleyer
Seminars in oncology 36 (3), 237-249, 2009
10002009
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
S Jiao, W Xia, H Yamaguchi, Y Wei, MK Chen, JM Hsu, JL Hsu, WH Yu, ...
Clinical Cancer Research 23 (14), 3711-3720, 2017
8632017
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
AM Gonzalez-Angulo, KM Timms, S Liu, H Chen, JK Litton, J Potter, ...
Clinical Cancer Research 17 (5), 1082-1089, 2011
7312011
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ...
Annals of Oncology 32 (5), 661-672, 2021
7022021
Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology
MB Daly, T Pal, MP Berry, SS Buys, P Dickson, SM Domchek, ...
Journal of the National Comprehensive Cancer Network 19 (1), 77-102, 2021
6252021
Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1
JH Cha, WH Yang, W Xia, Y Wei, LC Chan, SO Lim, CW Li, T Kim, ...
Molecular cell 71 (4), 606-620. e7, 2018
5842018
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
J Mersch, MA Jackson, M Park, D Nebgen, SK Peterson, C Singletary, ...
Cancer 121 (2), 269-275, 2015
5812015
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
F André, R O'Regan, M Ozguroglu, M Toi, B Xu, G Jerusalem, N Masuda, ...
The lancet oncology 15 (6), 580-591, 2014
5702014
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller
AM Gonzalez-Angulo, JK Litton, KR Broglio, F Meric-Bernstam, R Rakkhit, ...
Journal of clinical oncology 27 (34), 5700, 2009
5542009
NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017
MB Daly, R Pilarski, M Berry, SS Buys, M Farmer, S Friedman, JE Garber, ...
Journal of the National Comprehensive Cancer Network 15 (1), 9-20, 2017
5072017
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer
S Yennurajalingam, S Frisbee-Hume, JL Palmer, MO Delgado-Guay, ...
Journal of Clinical Oncology 31 (25), 3076-3082, 2013
3932013
NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines
MB Daly, R Pilarski, MB Yurgelun, MP Berry, SS Buys, P Dickson, ...
Journal of the National Comprehensive Cancer Network 18 (4), 380-391, 2020
372*2020
Genetic/familial high-risk assessment: breast and ovarian
MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ...
Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010
3522010
Current landscape of immunotherapy in breast cancer: a review
S Adams, ME Gatti-Mays, K Kalinsky, LA Korde, E Sharon, ...
JAMA oncology 5 (8), 1205-1214, 2019
3322019
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
JK Litton, SA Hurvitz, LA Mina, HS Rugo, KH Lee, A Gonçalves, S Diab, ...
Annals of Oncology 31 (11), 1526-1535, 2020
2772020
Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline
NM Tung, JC Boughey, LJ Pierce, ME Robson, I Bedrosian, JR Dietz, ...
Journal of clinical oncology 38 (18), 2080-2106, 2020
2602020
PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014; 2: 361–370. doi: 10.1158/2326-6066
EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ...
CIR-13-0127.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
241
Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer
S Bayraktar, LF Hernadez‐Aya, X Lei, F Meric‐Bernstam, JK Litton, L Hsu, ...
Cancer 118 (5), 1202-1211, 2012
2212012
系统目前无法执行此操作,请稍后再试。
文章 1–20